Ginebra ferreiraSep 30
Interesting
This research is Trending!
View all ESC 2026 trials
Catheter-Directed Thrombolysis in Intermediate-High–Risk Pulmonary Embolism
Key result
Catheter-directed thrombolysis reduces mortality, PE recurrence, or decompensation ~90% vs standard anticoagulation.
- RR 0.10
- 95% CI 0.02 to 0.44
- P<0.001
- n=558
Why the trial?
In intermediate-high-risk pulmonary embolism, anticoagulation alone leaves some patients to deteriorate while systemic thrombolysis causes major bleeding, and catheter-directed thrombolysis had not been proven in a randomised outcomes trial. Prague 26 addressed that gap.
Does conventional catheter-directed thrombolysis reduce the composite of all-cause mortality, pulmonary-embolism recurrence, or cardiorespiratory decompensation or collapse within seven days in patients with acute intermediate-high-risk pulmonary embolism compared to standard anticoagulation alone?
Population
558 patients with acute intermediate-high-risk PE; median age 64, 41% women
Comparison
Catheter-directed thrombolysis vs standard anticoagulation alone
Design
Multicenter randomized trial (11 Czech centres)
Follow-up
7 days (primary endpoint)
Authors
Discussion
1 takeKey questions
Member takes
Where experts stand
Experts see Prague 26 as a strong signal favoring catheter-directed thrombolysis in intermediate-high-risk PE, but several caution that the results do not yet mandate routine use given bleeding concerns and the need for more data.
Clinicians broadly welcome the clear reduction in the primary composite endpoint, calling the results promising for catheter-directed thrombolysis in this population. However, reaction stops short of declaring a new standard of care, with voices flagging intracranial bleeding events and emphasizing that further evidence is needed before routine adoption. The live question is whether these findings will shift guidelines toward earlier catheter-based intervention or whether longer-term safety and efficacy data will be required first.
Still unclear
Whether the benefit seen at 7 days persists at longer follow-up remains unknown. The intracranial hemorrhage events in the thrombolysis arm raise unresolved questions about the net clinical benefit in broader practice. It is also unclear whether guideline committees will view a single trial as sufficient to recommend catheter-directed thrombolysis for this population.
Key expert perspectives
Promising results but not yet a mandate for routine CDT
Elad Asher highlights that catheter-directed thrombolysis reduced the 7-day primary endpoint from 6.8% to 0.7% (NNT=17), driven mainly by preventing cardiorespiratory deterioration. He calls the results promising but explicitly states they are not yet a mandate for routine CDT.
Distilled from their postX post
Anjan Gupta · University Hospitals of Cleveland · Aug 31 Results readout Notes that catheter-directed thrombolysis led to a lower risk of death, recurrent PE, or cardiorespiratory decompensation in intermediate-high-risk acute PE. X post
C. Michael Gibson · Interventional / Structural Cardiology · Beth Israel Deaconess Medical Center · Aug 31 Results readout Discussed Prague 26 results showing CDT reduced the primary composite endpoint versus standard anticoagulation. X post
Implication
Supports catheter-directed thrombolysis in intermediate-high-risk PE; confirms early-event reduction versus anticoagulation alone in this RCT.
Key Points
- To assess whether catheter-directed thrombolysis improves early clinical outcomes compared with standard anticoagulation alone in acute intermediate-high-risk pulmonary embolism.
- Multicenter randomized trial (PRAGUE-26) conducted across 11 centers in the Czech Republic involving 558 patients (median age 64 years; 41% women) with acute intermediate-high-risk pulmonary embolism.
- Patients were randomized to receive either conventional catheter-directed thrombolysis or standard anticoagulation alone, with primary clinical outcomes tracked through seven days.
- Catheter-directed thrombolysis significantly reduced the 7-day composite primary endpoint of all-cause mortality, pulmonary embolism recurrence, or cardiorespiratory decompensation (0.7% vs 6.8%; RR 0.10, 95% CI 0.02 to 0.44; p<0.001).
- Seven-day bleeding rates were similar between catheter-directed thrombolysis and anticoagulation alone (4.6% vs 5.0%; p=0.846), with two intracranial hemorrhages in the thrombolysis arm versus none in standard care.
Evidence details
What drove the result?
| Outcome | CDT | Anticoag |
|---|---|---|
| Death, PE recurrence, or cardiorespiratory decompensation/collapse at 7 days | 0.7% | 6.8% |
| Primary composite · RR 0.10 (95% CI 0.02-0.44; p<0.001); driven mainly by less decompensation or collapse | ||
Limitations & tradeoffs
Safety
Bleeding at 7 days was 4.6% vs 5.0% (p=0.846), with 2 intracranial bleeds in the CDT arm vs 0.
Statistical certainty
Very few primary events (0.7% with CDT) make the effect estimate imprecise (CI 0.02–0.44).
Subgroup caution
The benefit was driven mainly by decompensation or collapse, a softer component than death or recurrence.
Design limitations
Only 7 days of follow-up are reported in the record.
Structured PICO
Does conventional catheter-directed thrombolysis reduce the composite of all-cause mortality, pulmonary-embolism recurrence, or cardiorespiratory decompensation or collapse within seven days in patients with acute intermediate-high-risk pulmonary embolism compared to standard anticoagulation alone?
P
Population
558 patients (median age 64, 41% women) with acute intermediate-high-risk pulmonary embolism, followed for 7 days.
I
Intervention
Conventional catheter-directed thrombolysis (CDT)
C
Comparator
Standard anticoagulation alone
O
Outcome
Composite of all-cause mortality, pulmonary-embolism recurrence, or cardiorespiratory decompensation or collapse within seven dayscomposite
Main Result
Relative Risk: 0.1 (95% CI 0.02–0.44)
Absolute Event Rate: 0.7% vs 6.8%
p-value: p=<0.001
Catheter-directed thrombolysis significantly reduced the 7-day composite of mortality, PE recurrence, or decompensation in intermediate-high-risk pulmonary embolism compared to anticoagulation alone.
Coverage & sources
Journal, society, and media accounts. Useful signal, not independent expert judgment.
Cite This Study
Kroupa et al. (2026) conducted an RCT in acute intermediate-high-risk pulmonary embolism (n=558). conventional catheter-directed thrombolysis vs. standard anticoagulation alone was evaluated on composite of all-cause mortality, pulmonary-embolism recurrence, or cardiorespiratory decompensation or collapse within seven days (RR 0.10, 95% CI 0.02 to 0.44, p=<0.001). Catheter-directed thrombolysis reduced mortality, PE recurrence, or decompensation compared to standard anticoagulation alone (0.7% vs 6.8%; RR 0.10; 95% CI 0.02-0.44; p<0.001).